Abstract
The forty participants in a double blind controlled trial of parenteral methotrexate or gold for RA were followed up two years later. Fifty percent had remained on the original medication, 13/20 on MTX and 7/20 on gold. Only 5 and 3 of them respectively had no active joint swelling. No major differences between the two groups were seen.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Arthritis, Rheumatoid / drug therapy*
-
Drug Administration Schedule
-
Follow-Up Studies
-
Gold Sodium Thiomalate / administration & dosage*
-
Gold Sodium Thiomalate / adverse effects
-
Gold Sodium Thiomalate / therapeutic use
-
Humans
-
Infusions, Parenteral
-
Methotrexate / administration & dosage*
-
Methotrexate / adverse effects
-
Methotrexate / therapeutic use
-
Patient Dropouts
-
Time Factors
Substances
-
Gold Sodium Thiomalate
-
Methotrexate